

Whole Exome Sequencing characterization of Maturity-Onset Diabetes of the Young (MODY) and Type 2 Diabetes Mellitus patients reveals polygenic features and novel genetic variants of risk for MODY in a Latino population

Alberto Moscona-Nissan¹, Daniel Marrero-Rodríguez¹, Sergio Andonegui-Elguera¹, Eduardo Salif Luna-Ávila¹, Florencia Martínez-Mendoza¹, Sandra Vela-Patiño¹, Itzel Ramírez-Ramos, Kapy S León-Wu¹, Regina De Miguel-Ibáñez¹, Moisés Mercado¹, Keiko Taniguchi-Ponciano*¹, Aldo Ferreira-Hermosillo*¹.

1.- Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

*Corresponding authors:

Aldo Ferreira-Hermosillo, MD, PhD. e-mail: aldo.nagisa@gmail.com

Keiko Taniguchi-Ponciano, PhD. e-mail: keiko.taniguchi.p@gmail.com

Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social.
Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720 Phone: +54401021

Abstract

MODY is a heterogeneous group of monogenic forms of diabetes which present autosomal dominant inheritance in most cases, early onset, and lack of beta-cell autoimmunity. Up to 14 types of MODY have been described in genes with key roles in beta-cell differentiation, insulin secretion, and glucose metabolism. MODY misdiagnosis remains widespread, due to overlapping clinical phenotypes and remarkable variability within genetic variants across populations. Whole Exome Sequencing (WES) studies are needed to identify new genes in non-caucasian populations, as up to 77% of non-caucasian MODY patients do not harbor variants of significance in MODY-known genes. We characterized the genetic landscape of Mexican patients with MODY through WES, comparing data with T2DM and healthy subjects and proposed a novel set of genes in MODY in a Latino population.

We enrolled 51 participants divided into 3 groups, each comprising 17 subjects. Among MODY 1-14 genes, *ABCC8*, *CEL*, *BLK* and *HNF1A* genes presented the highest burden of variants across patients and found statistically significant differences in variant frequencies across groups in 5.3% of total variants. The only pathogenic variant in MODY cases that reached statistical significance ($p < 0.001$) across all groups was c.C1226T:p.T409I in *CEL* gene (deleterious by SIFT and probably damaging by PolyPhen) as was present in 58.9% of MODY patients, while in 0% of T2DM and healthy subjects. We detected other frequent pathogenic, possibly/probably damaging, deleterious, or CIP variants in Mexican MODY cases in genes such as *HNF1A* (c.A79C:p.I27L), and *APPL1* (c.A2099G:p.E700G) in 64.7% and 23.5% of MODY patients, respectively, but at similar frequencies in T2DM and healthy controls. The *CEL* pathogenic variants c.T2059G:p.S687A and c.G2065C:p.A689P were exclusively detected in 11.8% of MODY cases, while additional pathogenic variants in *GCK*, *NEUROD1*, *PAX4*, *ABCC8*, *KCNJ11*, and *BLK* were detected in 5.9% of cases.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Upon analyzing MODY patients individually, we unveiled the presence of one or more pathogenic/likely pathogenic/deleterious/CIP variants in 15/17 (88%) patients, and no variants in 12%. However, among those 15 cases, 12 patients presented two or more concomitant pathogenic/likely pathogenic/deleterious/CIP variants, revealing polygenic features in Mexican MODY patients.

WES mutational analysis revealed global and specific differences and differential enrichment in genes across groups. We propose a set of 15 candidate genes (*KCNJ2*, *OR2A1*, *RIMBP3*, *TRIM49C*, *CLEC18B*, *OR2T5*, *PEX5*, *AQP12B*, *OR51A4*, *SYT15*, *TRIM64*, *GSTT2B*, *SUSD2*, *TPTE*, *ZNF814*) which are significantly ($p < 0.01$) enriched in Mexican MODY patients and not in T2DM and healthy subjects, and 12 genes significantly enriched in Mexican T2DM and healthy groups, while not in MODY cases (*ABC7*, *ASAH2*, *OR2A42*, *RIMBP3C*, *NBPF6*, *PGA3*, *GOLGA8N*, *PABPC1*, *PABPC3*, *CNTNAP3B*, *POTEM*, *SPIN2A*).

Upon analysis of exclusively high impact variants and considering a cutoff value of an adjusted $p < 0.01$, we propose a set of 4 genes (*MAP2K3*, *PEX5*, *KMT2C*, and *ZNF717*) enriched in the MODY group when compared to both T2DM and healthy subjects and 10 genes (*ABC7*, *MUC6*, *PLIN4*, *OR8U1*, *NBPF11*, *PABPC3*, *RBMX*, *LILRA6*, *PABPC1*, and *ARHGEF5*) enriched in both Mexican T2DM and healthy groups.

MODY behaves as a genetically heterogeneous disease in the Mexican population. Although MODY 1-14 variants are frequent in Mexican patients, T2DM and healthy controls present similar frequency rates in most cases. MODY could behave as a polygenic disease in some patients and other genes may be involved in MODY Latino populations.

Introduction

Maturity-onset diabetes of the young (MODY) comprises a clinically heterogeneous group of monogenic forms of diabetes which present autosomal dominant inheritance in most cases, early onset in life, and absence of pancreatic beta-cell autoimmunity [1]. Up to 14 types of MODY have been described, related to genes that play key roles in pancreatic beta-cell differentiation, insulin secretion, and glucose metabolism [2]. The most frequently described genes encompass the hepatocyte nuclear factor 1 α (*HNF1A*), hepatocyte nuclear factor 4 α (*HNF4A*), and glucokinase (*GCK*) genes. Mutations in other genes such as *PDX1*, *HNF1B*, *NEUROD1*, *KLF11*, *CEL*, *PAX4*, *INS*, *BLK*, *ABCC8*, *KCNJ11*, and *APPL1* have been described but are rather infrequent [3-5].

Despite MODY accounts for 1-5% of all diabetes cases, it is estimated that only 3% of the total MODY patients are correctly diagnosed, while the rest are mistakenly classified as type 1 (T1DM) or type 2 diabetes mellitus (T2DM) in 36% and 51% of cases, respectively [6,7]. Misdiagnosis of MODY remains widespread, as physicians face several challenges such as overlapping clinical phenotypes between MODY and other types of diabetes [8]. Establishment of an accurate diagnosis is a fundamental and frequently neglected aspect in diabetes care, as a tailored management can be initiated when correctly diagnosing MODY [8]. MODY subtypes exhibit distinct rates of microvascular complications and best respond to a specific management, such as sulfonylureas (SUR) in the case of MODY 1 and 3, whereas MODY 2 does not require pharmacologic interventions in many cases [8]. Moreover,

appropriate diagnosis of MODY allows physicians to perform risk assessment in family members [9].

In addition to the clinical challenge imposed by overlapping phenotypes, a recent meta-analysis by Rafique et al. demonstrated remarkable variability within genetic variants in MODY patients across populations and pointed to the need of whole exome sequencing (WES) studies to identify new genes in non-caucasian populations with MODY [10]. It is of utmost importance to consider that most of the available literature and clinical diagnostic tools for MODY are based in European cohorts. Authors as Al-Kandari, et al. have reported that up to 77% of highly selected Middle-eastern patients with MODY suspect do not harbor variants of significance of known-MODY genes [11]. The registered proportion of MODY patients without a genetic diagnosis in Brazil ascends up to 73.9%, while in India, low genetic confirmation rates (6.6%) in patients with clinical diagnosis of MODY have been reported as well [12-15].

Regarding genetics of diabetes, research initiatives such as ProDiGY (Progress in Diabetes Genetics in the Youth), GUARDIAN (Genetics Underlying Diabetes in Hispanics) and the SIGMA Consortium (Studied from the Slim Initiative for Genomic Medicine), have evaluated genetic variants through genome wide-association studies and have characterized that some variants in *SLC16A11*, *HNF1A*, *CDKAL1*, *MTNR1B* and *TCF7L2* increase the risk of T2DM in the Latino population [16-18]. In Mexico, despite the high prevalence of diabetes (18.3%) associated with the even higher prevalence of overweight (38.3%) and obesity (36.9%), few studies have addressed the genetic factors related with MODY and its prevalence remains unknown [19].

The aim of this study was to analyze and characterize the genetic variants present in Mexican patients with MODY through Whole Exome Sequencing (WES). We compare its analysis with a cohort of patients recently diagnosed (< 10 years) with T2DM and with young healthy participants. To the best of our knowledge this is the first study to characterize MODY and T2DM genetic variants through WES in the Mexican population and propose novel genes involved in this disease.

Methods

We enrolled a total of 51 participants divided in three groups (MODY, T2DM and healthy controls), each having 17 subjects. All MODY and T2DM patients were treated and followed at the Endocrinology Service of the Hospital de Especialidades, Centro Médico Nacional, Siglo XXI of the Instituto Mexicano del Seguro Social, a mexican tertiary hospital and reference center located in Mexico City.

All participating subjects signed an informed consent. This study was reviewed and approved by the institutional review board and ethics review board of the Hospital de Especialidades, Centro Médico Nacional, Siglo XXI of the Instituto Mexicano del Seguro Social (R-2023-3601-003 and R-2023-3601-212). The study was conducted in accordance with the national clinical research laws and the Helsinki declaration.

Inclusion criteria for MODY group comprised adult (≥ 18 years) subjects, with a calculated Exeter score equal or greater than 36%, with low (< 1 U/Kg/day) or null insulin requirements,

preserved beta-cell function (measured through serum C-peptide levels >1 ng/mL) and lack of anti-GAD65 and IAA autoantibodies, with regular outpatient follow-up, and who consent to participate. T2DM group inclusion criteria comprehended adult (≥ 18 years) patients with T2DM diagnosed with less than 10 years of evolution, with any type of glycemic treatment (insulin \pm oral antidiabetic drugs) and any glycated hemoglobin (HbA1c). Inclusion criteria for healthy controls comprised adult (≥ 18 years) subjects, without any parental history of diabetes, with no metabolic diseases such as hypertension, diabetes or dyslipidemia.

From each patient, we collected data of clinical, biochemical, and anthropometric variables through physical and electronic medical records. We then calculated the Exeter score (available online at: <https://www.diabetesgenes.org/exeter-diabetes-app/ModyCalculator>) for all MODY cases and T2DM cases diagnosed under 35 years of age, and conducted statistical analyses using SPSS 24.0 (IBM, New York, USA) in order to apply Chi-square, T-Student test, or one-way ANOVA when applicable to compare the group's baseline characteristics, as shown in Table 1. The level of significance was considered at a p-value <0.05.

In order to carry genetic testing, we extracted peripheral blood from all subjects and extracted leukocyte DNA with Qiagen kit protocol. We carried out DNA purification using the DNAeasy (Qiagen Inc, CA, USA) blood and tissue kit. Leukocytes were lysed using proteinase K and the cell lysate was subsequently transferred to the DNAeasy columns. Once the DNA was captured in the columns, washes were carried out with the kit's specific buffers to subsequently perform the elution of the DNA with molecular biology grade water. The high molecular weight DNA was evaluated to find the highest quality and purity using the NanoDrop2000 and the TapeStation (Agilent Technologies, CA, USA).

Whole Exome Sequencing (WES)

The genomic DNA (gDNA) was shipped to the Genomics Core Lab of the Tecnológico de Monterrey for exome sequencing. gDNA was quantified using Qubit dsDNA BR Assay Kit (Invitrogen, Carlsbad, CA, USA). Quality was determined spectrophotometrically using a Nanodrop One spectrophotometer (Thermo Fisher Scientific, Waltham MA, USA). WES libraries were prepared using Illumina DNA Prep with Exome 1.0 Enrichment (Illumina, San Diego CA, United States). All libraries were quantified with the Qubit dsDNA BR Assay Kit (Invitrogen, Carlsbad, CA, USA), library size was analyzed in S2 Standard DNA Cartridge for Sep 400 (BiOptic, New Taipei City, Taiwan), and sequencing was performed in a NovaSeq 6000 (Illumina, San Diego CA, United States) in a 150 bp paired-end configuration.

Computational Analysis WES

Preprocessed sequences were aligned to the human reference sequence (hg38) using the Illumina-Dragen Enrichment pipeline (Illumina, San Diego CA, United States). This pipeline was set to produce copy number variants (--enable-cnv true). The BAM files resulting from the enrichment were removed from PCR duplicates using Picard Tools (<http://broadinstitute.github.io/picard>). Each BAM file was used to obtain the somatic variants using the GATK pipeline, and variants were annotated using ANNOVAR according to the following databases: Clinvar, gnomAD, refGene, cytoBand, exac03, avsnp147, dbnsfp30a. The VCF files were then transformed and annotated using the vcf2maf tool and VEP [20] 112 release database of ENSEMBL, IMPACT annotation was used to filter variants with

“high” value. In addition, the Maftools package version 2.21.1 [21] in R language version 4.4.1 was used to analyze and visualize the landscape of critical variants. The groups were constructed using `read.maf` and `merge_maf` functions, to compare groups `mafCompare` function was used with a Fisher test on a 2x2 contingency table. Maftools visualization tools were used to generate the graphs.

Variant analysis of MODY-known and T2DM genes

For each included subject, we filtered all MODY 1-14 and T2DM genetic variants in order to evaluate the frequency at which every variant was detected in every patient and groups. We tracked an additional set of genes with previous reports of involvement in MODY such as *RFX6*, *WFS1*, *NKX6-1*, *AKT2*, *NKX2-2*, *PCBD1*, *MTOR*, *TBC1D4*, *CACNA1E*, and *MXN1*. Group frequencies per variant were compared across MODY versus T2DM, MODY versus healthy subjects and through all groups, using Chi-square calculation with SPSS 24.0 (IBM, New York, USA). The clinical impact of each genetic variant was categorized according to the ClinSig, SIFT, PolyPhen-2 (HUMVAR), and ClinVar databases. In the case of ClinVar dataset (<https://www.ncbi.nlm.nih.gov/clinvar/>) we reported the clinical impact of each variant only for MODY or monogenic diabetes. When a variant lacked a clinical impact report in monogenic diabetes through ClinVar, we reported the variant as unknown (Table 2).

We carried genetic analysis upon individualized cases to explore the association of concomitant variants in single MODY patients and grouped all the pathogenic, probably and possibly damaging, deleterious, and variants with conflicting interpretations of pathogenicity (CIP) found per MODY patient in association with their current treatment and calculated Exeter score, as shown in Table 3. We further constructed a clustered heatmap and created a Principal Component Analysis (PCA) plot on ClustVis, an online web-tool using R package (version 0.7.7) [<https://biit.cs.ut.ee/clustvis/>] to present all detected variants across patients and groups.

Results

A total of 51 patients were included in our study across 3 groups (MODY, T2DM, and healthy controls) each comprising 17 subjects. The mean age at evaluation of MODY patients was 21.2 ± 5.7 years, 43.5 ± 10.1 years in T2DM patients, and 25.5 ± 3.4 years in healthy controls. Mean age at diabetes diagnosis was significantly lower in the MODY group, being 21.2 years, compared to 43.5 years in the T2DM group ($p < 0.001$). No significant differences were found regarding gender among groups ($p = 0.059$). Parental history of diabetes was present in 88% of MODY group patients, while was present in 53% of T2DM subjects ($p = 0.023$).

MODY and T2DM patients presented similar mean HbA1c levels (7.1 and 7.0%, respectively) as 47 and 53% of patients reached treatment goals, respectively. The T2DM group presented the highest frequency of overweight and obesity, with a mean BMI of 37.3 ± 10.4 kg/m² ($p < 0.001$) in contrast with a mean BMI of 25.1 ± 4.7 kg/m² and 24.2 ± 3.0 kg/m², in MODY and healthy groups, respectively. Similarly, mean waist circumference was greater in T2DM when compared to other groups ($p < 0.001$). Upon evaluation of patient comorbidities, the T2DM group exhibited the highest frequency of systemic hypertension being 76% versus 5.8% in the MODY group ($p < 0.001$). Conversely, dyslipidemia was more

prevalent among MODY patients, with a frequency of 76% versus 27% ($p < 0.001$). The mean Exeter score in MODY patients was 63.5 ± 14.3 (ranging from 35.8 to 75.5%), while the mean Exeter was 4.6% in T2DM when possible to calculate.

Regarding patient management, 94% of MODY patients underwent pharmacologic treatment for diabetes, as one MODY patient was effectively treated with lifestyle modifications. Among MODY patients, 58% were treated with metformin, 41% with insulin, 35% with SUR, and 17.5% with DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Antidiabetic treatments did not differ among groups, except for SUR agents ($p=0.033$) as only 5.9% of T2DM patients received SUR treatment, as shown in Table 1.

Table 1. Sociodemographic and clinical data of included participants

	MODY (n=17)	Type 2 Diabetes (n=17)	Healthy controls (n=17)	p-value
Gender				
Male (%)	4 (24)	3 (18)	9 (53)	0.059
Female (%)	13 (76)	14 (82)	8 (47)	
Age at diagnosis, years				
Mean \pm SD	21.2 \pm 5.7	43.5 \pm 10.1	NA	<0.001
Age at evaluation, years				
Mean \pm SD	34.1 \pm 10.7	52.2 \pm 11.1	25.5 \pm 3.4	<0.001
Biochemical parameters				
Mean HbA1c \pm SD, %	7.12 \pm 1.1	7.0 \pm 1.0	NA	0.393
Mean HbA1c \pm SD, mmol/mol	54.3 \pm 12.0	52 \pm 10.9	NA	
Under treatment goals HbA1c < 7 (%)	8 (47.0)	9 (52.9)	NA	0.73
Parental history of diabetes				
n (%)	15 (88.2)	9 (52.9)	0 (0)	<0.001 (All) 0.023 (MODY vs T2DM)
Comorbidities				
Mean BMI \pm SD, kg/m ²	25.1 \pm 4.7	37.3 \pm 10.4	24.2 \pm 3.0	<0.001
Waist circumference, cm	88.0 \pm 12.0	109.5 \pm 19.0	80.8 \pm 9.1	<0.001
Overweight (%)	4 (23.5)	3 (17.6)	6 (35.2)	0.485
Obesity (%)	2 (11.7)	12 (70.5)	1 (5.8)	<0.001
Normal weight (%)	10 (58.8)	1 (5.8)	9 (52.9)	0.002
Underweight (%)	1 (5.8)	1 (5.8)	1 (5.8)	1.00
Hypertension (%)	1 (5.8)	13 (76.4)	0 (0)	<0.001
Dyslipidemia (%)	13 (76.4)	5 (27.7)	0 (0)	<0.001
Calculated Exeter score				
Mean \pm SD	63.5 \pm 14.3	4.6 \pm 0	NA	<0.001
Min - Max	35.8 - 75.5	4.6 - 4.6	NA	
Current treatment				
Insulin (%)	7 (41.1)	7 (41.1)	NA	1.00
Metformin (%)	10 (58.8)	14 (82.3)	NA	0.13
Sulfonylureas (%)	6 (35.2)	1 (5.8)	NA	0.033
DPP-4 inhibitors (%)	3 (17.6)	6 (35.2)	NA	0.24
GLP-1 agonists (%)	3 (17.6)	8 (47.0)	NA	0.066
SGLT2 inhibitors (%)	3 (17.6)	8 (47.0)	NA	0.066
Thiazolidinediones (%)	1 (5.8)	2 (11.7)	NA	0.36
Diet and exercise only (%)	1 (5.8)	0 (0)	NA	0.31

Upon evaluation of genetic variants of MODY 1-14 genes through WES across all patients, we found 92 distinct exonic genetic variants in the MODY 1-14 genes. We did not detect any variants in *INS* (previously MODY 10). *ABCC8*, *CEL*, *BLK* and *HNF1A* presented the highest burden of variants across all patients. When comparing the MODY group with T2DM and healthy controls, we found statistically significant differences in variant frequencies in 5.3% of total variants, as shown in Table 2.

Table 2. Frequency of genetic variants of MODY and Type 2 Diabetes Mellitus

Genetic variant	Clin Sig	SI FT	Poly Phen	Clin Var	MODY (n=17)		T2DM (n=17)		Healthy (n=17)		MODY vs T2DM p-value	MODY vs Healthy p-value	All groups p-value
					n	%	n	%	n	%			
HNF4A (MODY 1)													
c.C341T:p.T114I	B/LB	T	B	LB	4	23.5	1	5.9	0	0.0	0.146	0.033	0.056
c.C1017T:p.A339A	LB	-	-	LB	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C126T:p.A42A	B	-	-	B	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G717A:p.V239V	CIP	-	-	CIP	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
GCK (MODY 2)													
c.C297T:p.S99S	-	-	-	LB	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C642T:p.Y214Y	B/LB	-	-	LB	2	11.8	0	0.0	0	0.0	0.145	0.145	0.125
c.T668C:p.M223T	-	D	B	LP	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
HNF1A (MODY 3)													
c.C51G:p.L17L	B	-	-	B	12	70.6	14	82.4	12	70.6	0.419	1.00	0.662
c.A79C:p.I27L	B	T	B	CIP	11	64.7	11	64.7	10	58.8	1.00	0.724	0.92
c.G864C:p.G288G	B	-	-	B	9	52.9	14	82.4	15	88.2	0.067	0.024	0.041
c.C1375T:p.L459L	B	-	-	B	11	64.7	10	58.8	8	47.1	0.724	0.3	0.571
c.G1460A:p.S487N	B	T	B	B	11	64.7	10	58.8	8	47.1	0.724	0.3	0.571
c.A1741G:p.S581G	B	T	B	B	17	100	17	100	17	100	NA	NA	NA
c.C293T:p.A98V	B	T	B	B/LB	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.865dupC:p.G292Rfs*25	P	-	-	P	0	0.0	2	11.8	1	5.9	0.145	0.31	0.346
c.G1545A:p.T515T	B	-	-	B	0	0.0	3	17.6	7	41.2	0.07	0.003	0.01
c.G92A:p.G31D	CIP	T	B	B/LB	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.1137delT:p.V380Sfs*4	P	-	-	P	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
PDX 1 (MODY 4)													
c.G234T:p.A78A	-	-	-	LB	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G657C:p.G219G	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C97A:p.P33T	CIP	D	D	CIP	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C280T:p.H94Y	-	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C693T:p.S231S	B	-	-	LB	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A338G:p.N113S	-	T	B	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
HNF1B (MODY 5)													
c.C978T:p.Y326Y	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361

c.C606G:p.N202K	B/LB	-	B	B	2	11.8	0	0.0	0	0.0	0.145	0.145	0.125
NEUROD1 (MODY 6)													
c.A133G:p.T45A	B	T	B	B	16	94.1	17	100	16	94.1	0.145	0.54	0.346
c.C590A:p.P197H	B	D	B	B	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
KLF11 (MODY 7)													
c.G799A:p.D267N	-	T	P	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G457A:p.A153T	-	T	B	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G1054C:p.A352P	-	T	B	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A185G:p.Q62R	B/LB	T	B	LB	3	17.6	1	5.9	2	11.8	0.287	0.628	0.567
c.T996C:p.P332P	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A1185T:p.V395V	-	-	-	-	17	100	17	100	17	100	NA	NA	NA
c.828_829insTCTGTC:p.V280_P281insSV	-	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
CEL (MODY 8)													
c.C1710T:p.P570P	LB	-	-	-	3	17.6	9	52.9	9	52.9	0.031	0.031	0.054
c.2033_2065del:p.P693_V703del	-	-	-	-	0	0.0	2	11.8	3	17.6	0.145	0.07	0.212
c.C402G:p.G134G	B	-	-	B/LB	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.2112_2113insCCCACGGG TGACTCCGAGACCGCCC CCGTGCCG:p.S720_G721insETAPVPPTGDS	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C1164T:p.T388T	-	-	-	-	3	17.6	0	0.0	1	5.9	0.07	0.287	0.15
c.C2064G:p.G688G	B	-	-	-	3	17.6	0	0.0	0	0.0	0.07	0.07	0.041
c.C603T:p.F201F	-	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.C1226T:p.T409I	-	D	D	-	10	58.8	0	0.0	0	0.0	<0.001	<0.001	<0.001
c.T2059G:p.S687A	-	D	P	-	2	11.8	0	0.0	0	0.0	0.145	0.145	0.125
c.G2065C:p.A689P	-	D	D	-	2	11.8	0	0.0	0	0.0	0.145	0.145	0.125
c.G1801C:p.A601P	-	D	P	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.G41C:p.C14S	-	D	P	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.T1454C:p.I485T	B/LB	D	D	B	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.G2021A:p.G674D	-	T	B	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.2032dupC:p.V681Rfs*6	P	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
PAX4 (MODY 9)													
c.A1046G:p.X349W	B	-	-	-	16	94.1	17	100	17	100	0.31	0.31	0.361
c.A986C:p.H329P	B	T	B	VUS	16	94.1	17	100	17	100	0.31	0.31	0.361
c.A543G:p.Q181Q	B/LB	-	-	LB	1	5.9	2	11.8	2	11.8	0.54	0.545	0.801
c.G680A:p.R227Q	-	D	D	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.G116A:p.R39Q	LB	D	D	LB	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
INS (MODY 10)													
No variants found	-	-	-	-	0	0	0	0	0	0	NA	NA	NA
BLK (MODY 11)													
c.T843C:p.F281F	B	-	-	B	17	100	16	94.1	17	100	0.31	NA	0.361

c.T330C:p.S110S	B	-	-	B	8	47.1	7	41.2	8	47.1	0.73	1.00	0.924
c.C435T:p.A145A	B	-	-	B	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A1178C:p.E393A	B	D	P	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G258A:p.Q86Q	B	-	-	B	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A974C:p.K325T	B/LB	D	P	B	1	5.9	0	0.0	1	5.9	0.31	1.00	0.594
c.G157A:p.D53N	-	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C116T:p.P39L	B/LB	D	B	B	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C570T:p.S190S	-	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.C711T:p.P237P	B/LB	-	-	LB	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
ABCC8 (MODY 12)													
c.T207C:p.P69P	B/LB	-	-	B	16	94.1	16	94.1	14	82.4	1.00	0.287	0.412
c.G4711A:p.V1571I	B/LB	T	B	LB	0	0.0	3	17.6	2	11.8	0.07	0.145	0.212
c.G4102T:p.A1368S	B	T	B	B	14	82.4	13	76.5	12	70.6	0.671	0.419	0.721
c.G3816A:p.R1272R	B	-	-	B	10	58.8	7	41.2	7	41.2	0.303	0.303	0.492
c.C3609T:p.A1203A	B	-	-	VUS	7	41.2	3	17.6	5	29.4	0.132	0.473	0.322
c.G2498A:p.R833H	-	D	P	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C2482T:p.L828L	B	-	-	B	1	5.9	2	11.8	3	17.6	0.545	0.287	0.567
c.C1683T:p.H561H	B	-	-	B	12	70.6	4	23.5	11	64.7	0.006	0.714	0.011
c.A1164G:p.G388G	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G3070A:p.V1024I	-	T	B	VUS	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G1944A:p.K648K	B	-	-	B	4	23.5	1	5.9	2	11.8	0.146	0.368	0.314
c.C4221T:p.D1407D	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C330T:p.A110A	B	-	-	B	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G102A:p.V34V	B	-	-	VUS	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C2997T:p.C999C	B	-	-	VUS	1	5.9	0	0.0	1	5.9	0.31	1.00	0.594
c.G1720A:p.V574M	-	T	D	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.C2274T:p.T758T	B/LB	-	-	LB	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
KCNJ11 (MODY 13)													
c.G748A:p.V250I	B/LB	T	B	LB	14	82.4	13	76.5	12	70.6	0.671	0.419	0.721
c.A67G:p.K23E	DR	T	B	LB	13	76.5	13	76.5	12	70.6	1.00	0.697	0.902
c.C547G:p.L183V	B/LB	T	B	B	0	0.0	2	11.8	2	11.8	0.145	0.145	0.338
c.C309T:p.A103A	B/LB	-	-	LB	5	29.4	3	17.6	2	11.8	0.419	0.203	0.419
c.C540G:p.L180L	CIP	-	-	B	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
APPL1 (MODY 14)													
c.A1736G:p.E579G	-	D	P	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A2099G:p.E700G	-	D	B	-	4	23.5	2	11.8	4	23.5	0.368	1.00	0.608
c.A1206G:p.P402P	B	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A69G:p.L23L	-	-	-	B	2	11.8	1	5.9	0	0.0	0.545	0.145	0.346
c.T256C:p.L86L	B	-	-	B/LB	2	11.8	0	0.0	0	0.0	0.145	0.145	0.125
SLC16A11 (T2DM)													
C1255A:p.P419T	-	T	P	-	11	64.7	7	41.2	10	58.8	0.169	0.724	0.357

c.G946A:p.G316S	-	T	B	-	11	64.7	7	41.2	10	58.8	0.169	0.724	0.357
c.T489C:p.L163L	-	-	-	-	11	64.7	7	41.2	11	64.7	0.169	1.00	0.278
c.A308G:p.D103G	-	D	B	-	10	58.8	7	41.2	11	64.7	0.303	0.724	0.357
c.G265A:p.V89I	-	T	B	-	9	52.9	7	41.2	10	58.8	0.492	0.73	0.577
c.G238T:p.A80S	-	T	B	-	1	5.9	1	5.9	0	0.0	1.00	0.31	0.594
c.G969A:p.V323V	-	-	-	-	2	11.8	0	0.0	1	5.9	0.145	0.545	0.346
CDKAL1 (T2DM)													
c.G1536A:p.S512S	-	-	-	-	14	82.4	13	76.5	15	88.2	0.671	0.628	0.667
c.A1227G:p.P409P	-	-	-	-	4	23.5	3	17.6	2	11.8	0.671	0.368	0.667
c.C1406T:p.A469V	-	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C532A:p.L178M	-	T	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C1226T:p.P409L	-	D	B	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
MTNR1B (T2DM)													
c.G71A:p.G24E	-	T	B	-	0	0.0	2	11.8	0	0.0	0.145	NA	0.125
c.A728G:p.K243R	-	T	B	-	0	0.0	1	5.9	1	5.9	0.31	0.31	0.594
c.G692A:p.R231H	-	D	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C448T:p.R150X	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C312T:p.D104D	-	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.T725C:p.L242P	-	T	B	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
TCF7L2 (T2DM)													
c.C1498A:p.P500T	-	T	D	-	2	11.8	4	23.5	1	5.9	0.368	0.545	0.314
c.C1535A:p.P512H	B	D	B	-	1	5.9	3	17.6	1	5.9	0.287	1.00	0.412
c.T1737G:p.A579A	B	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.1446dupA:p.C486Vfs*8	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.T418C:p.Y140H	-	D	D	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G1542C:p.P514P	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.T599C:p.L200P	-	D	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G40A:p.A14T	-	D	D	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.T1537G:p.S513A	-	T	P	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
HNFI1A (T2DM)													
c.C51G:p.L17L	B	-	-	VUS	12	70.6	14	82.4	12	70.6	0.419	1.00	0.662
c.A79C:p.I27L	B	T	B	B	11	64.7	11	64.7	10	58.8	1.00	0.724	0.92
c.G864C:p.G288G	B	-	-	VUS	9	52.9	14	82.4	15	88.2	0.067	0.024	0.041
c.C1375T:p.L459L	B	-	-	B	11	64.7	10	58.8	8	47.1	0.724	0.3	0.571
c.G1460A:p.S487N	B	T	B	B	11	64.7	10	58.8	8	47.1	0.724	0.3	0.571
c.A1741G:p.S581G	B	T	B	B	17	100	17	100	17	100	NA	NA	NA
c.C293T:p.A98V	B	T	B	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.865dupC:p.G292Rfs*25	P	-	-	-	0	0.0	2	11.8	1	5.9	0.145	0.31	0.346
c.G1545A:p.T515T	B	-	-	VUS	0	0.0	3	17.6	7	41.2	0.07	0.003	0.01
c.G92A:p.G31D	CIP	T	B	LB	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.1137delT:p.V380Sfs*4	P	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361

ClinSig: B=Benign, "-" = Unknown, DR= Drug Response, B/LB= Benign/ Likely Benign, LB= Likely benign, CIP= Conflicting interpretation of pathogenicity, P= Pathogenic. SIFT: T= Tolerable; D= deleterious, "-" = Unknown. PolyPhen: D=Probably damaging, P=Possibly damaging, B=benign, "-" = Unknown/Not reported. ClinVar: VUS=Variant of Uncertain Significance, P=Pathogenic, LP=Likely Pathogenic, B=Benign, LB=Likely Benign, CIP=Conflicting interpretation of pathogenicity.

Five genetic variants displayed statistically significant different frequencies among the three groups. Firstly, c.C1226T:p.T409I and c.C2064G:p.G688G in the *CEL* gene were found in 58.9% and 17.6% of MODY cases versus 0% in other groups. Variant c.C1683T:p.H561H in *ABCC8* was found in 70.6% of MODY cases, 23.5% of T2DM, and 64.7% of healthy subjects, while variants c.G864C:p.G288G and c.G1545A:p.T515T in *HNF1A* presented an increased frequency in T2DM and healthy controls over MODY patients. When considering statistical significant differences across MODY and healthy controls exclusively, the c.C341T:p.T114I variant in *HNF4A* was detected in 23.5% of MODY cases versus 0% of healthy controls (Table 2).

Upon clinical impact consideration based on predicting tools, among the 92 variants found, 3 were pathogenic and 4 presented a conflicting interpretation of pathogenicity (CIP) according to ClinSig; 17 were deleterious according to the SIFT score; 7 were probably damaging (D) and 8 possibly damaging (P) by PolyPhen-2 score; 3 presented a CIP, 2 were likely pathogenic (LP), 2 pathogenic and 5 were variants of uncertain significance (VUS), as shown in Table 2. *CEL* gene (MODY 8) presented the highest burden of pathogenic/damaging variants (7 in total), followed by *HNF1A* and *BLK* (3 in total each).

We detected the variant c.C1226T:p.T409I in *CEL* gene (deleterious by SIFT and probably damaging by PolyPhen) in 58.9% (10/17) of MODY patients, while in 0% of T2DM and healthy subjects, being the only pathogenic variant in MODY cases that reached statistical significance ($p < 0.001$) across all groups.

Frequent pathogenic, possibly/probably damaging, deleterious, or CIP variants that were detected in Mexican MODY cases include c.A79C:p.I27L in *HNF1A* (CIP by ClinVar) and c.A2099G:p.E700G in *APPL1* gene (deleterious by SIFT). The first was found in 64.7% of MODY patients while the second in 23.5% of MODY cases, however both presented similar frequencies in T2DM and healthy controls. Variants c.T2059G:p.S687A and c.G2065C:p.A689P in *CEL* were detected in 11.8% of MODY cases, while in 0% of T2DM and healthy controls, both being deleterious by SIFT and probably/possibly damaging by PolyPhen.

Other pathogenic, possibly/probably damaging, deleterious, or CIP variants present in 5.9% of MODY cases and 0% of T2DM and healthy subjects include c.1137delT:p.V380Sfs*4 in *HNF1a* (pathogenic according to ClinSig and ClinVar), c.T668C:p.M223T in *GCK* (deleterious by SIFT and likely pathogenic by ClinVar), *NEUROD1* c.C590A:p.P197H (deleterious by SIFT), *CEL* c.G1801C:p.A601P, c.G41C:p.C14S, c.T1454C:p.I485T (all deleterious by SIFT and possibly/probably damaging by PolyPhen), *CEL* c.2032dupC:p.V681Rfs*6 (pathogenic by ClinSig), *PAX4* c.G680A:p.R227Q (deleterious by SIFT and probably damaging by PolyPhen), *ABCC8* (probably damaging by PolyPhen), and *KCNJ11* c.C540G:p.L180L (CIP by ClinSig). Moreover, the variant c.A974C:p.K325T in *BLK*

(deleterious by SIFT and possibly damaging by PolyPhen) was detected in a single MODY patient (5.9%) but was present in the same frequency in healthy controls (Table 2).

No pathogenic variants were detected in MODY cases for *HNF4A*, *PDX1*, *HNF1B*, *NEUROD1*, *KLF11*, and *INS* genes. Additionally, to the best of our knowledge this is the first study to report new variants in MODY patients such as *KLF11* c.828_829insTCTGTC:p.V280_P281insSV, *CEL* c.C1164T:p.T388T, *CEL* c.C603T:p.F201F, and *BLK* c.C570T:p.S190S.

We further evaluated the frequency of genetic variants present in other genes associated with MODY (*RFX6*, *WFS1*, *NKX6-1*, *AKT2*, *NKX2-2*, *PCBD1*, *MTOR*, *TBC1D4*, *CACNA1E*, and *MNX1*), finding no statistically significant differences across groups (Table 3). For the *WFS1* gene, a deleterious/probably damaging variant (c.G2596T:p.D866Y) was detected exclusively in a MODY case (patient #10), while we detected other deleterious/probably damaging variants that were present at similar frequency rates in T2DM and healthy controls. No variants of interest were found in *NKX6-1*, *AKT2*, *NKX2-2*, *PCBD1*, *MTOR*, *CACNA1E*, *TBC1D4*, and *MNX1* genes (Table 3).

Table 3. Frequency of genetic variants among other genes associated with MODY (*RFX6*, *WFS1*, *NKX6-1*, *AKT2*, *NKX2-2*, *PCBD1*, *MTOR*, *TBC1D4*, *CACNA1E*, *MNX1*)

Genetic variant	Clin Sig	Poly SIFT	Clin Phen	Clin Var	MODY (n=17)		T2DM (n=17)		Healthy (n=17)		MODY vs T2DM p-value	MODY vs Healthy p-value	All groups p-value
					n	%	n	%	n	%			
RFX6													
c.T1383C:p.T461T	LB	-	-	-	12	70.6	11	64.7	8	47.1	0.714	0.163	0.343
c.T1542C:p.N514N	LB	-	-	-	12	70.6	11	64.7	8	47.1	0.714	0.163	0.343
c.C1782T:p.H594H	LB	-	-	-	12	70.6	11	64.7	8	47.1	0.714	0.163	0.343
c.T1914C:p.G638G	LB	-	-	-	12	70.6	11	64.7	8	47.1	0.714	0.163	0.343
c.G985A:p.V329I	B	Tol	B	-	3	17.6	2	11.8	2	11.8	0.628	0.628	0.847
c.C544T:p.L182F	-	Del	D	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
WFS1													
c.C684G:p.R228R	B	-	-	-	16	94.1	16	94.1	16	94.1	1.00	1.00	1.00
c.G997A:p.V333I	B	Tol	B	-	16	94.1	17	100.0	16	94.1	0.31	1.00	0.594
c.C1185T:p.V395V	B	-	-	-	15	88.2	16	94.1	16	94.1	0.545	0.545	0.762
c.C1500T:p.N500N	B	-	-	-	15	88.2	16	94.1	16	94.1	0.545	0.545	0.762
c.G1832A:p.R611H	B	Tol	B	-	15	88.2	16	94.1	14	82.4	0.545	0.628	0.567
c.G2433A:p.K811K	B	-	-	B	15	88.2	16	94.1	16	94.1	0.545	0.545	0.762
c.A2565G:p.S855S	B	-	-	-	16	94.1	16	94.1	16	94.1	1.00	1.00	1.00
c.G1726A:p.G576S	B/LB	Del	B	B	1	5.9	1	5.9	2	11.8	1.00	0.545	0.762
c.C1023T:p.F341F	B	-	-	-	2	11.8	1	5.9	2	11.8	0.545	1.00	0.801
c.C1725T:p.A575A	B	-	-	-	2	11.8	0	0.0	2	11.8	0.145	1.00	0.338
c.G2322A:p.K774K	B	-	-	-	1	5.9	0	0.0	2	11.8	0.31	0.545	0.346

c.G1367A:p.R456H	B/LB	Tol	D	-	2	11.8	0	0.0	2	11.8	0.145	1.00	0.338
c.C2666T:p.A889V	-	Del	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C342T:p.A114A	B/LB	-	-	-	0	0.0	2	11.8	1	5.9	0.145	0.31	0.346
c.G226A:p.G76S	-	Tol	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A2432G:p.K811R	-	Tol	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G817A:p.E273K	VUS	Del	B	-	1	5.9	1	5.9	0	0.0	1.00	0.31	0.594
c.G2623A:p.V875M	LB	Tol	B	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.G2596T:p.D866Y	-	Del	D	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.G2040A:p.E680E	B/LB	-	-	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
NKX6-1													
c.414_415insTCCTCCGCC TCTGCC:p.A138_A139ins SSASA	-	-	-	-	1	5.9	0	0.0	1	5.9	0.31	1.00	0.594
c.G85A:p.A29T	-	Tol	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G462A:p.A154A	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
AKT2													
c.G1110T:p.P370P	B	-	-	B	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
NKX2-2													
c.A64G:p.N22D	-	T	B	-	1	5.9	0	0.0	0	0.0	0.31	0.31	0.361
c.G365C:p.G122A	-	T	B	-	1	5.9	0	0.0	1	5.9	0.31	1.00	0.594
PCBD1													
No variants found	-	-	-	-	0	0.0	0	0.0	0	0.0	NA	NA	NA
MTOR													
c.G4731A:p.A1577A	B	-	-	-	15	88.2	15	88.2	17	100.0	1.00	0.145	0.338
c.C2997T:p.N999N	-	-	-	-	15	88.2	17	100.0	16	94.1	0.145	0.545	0.346
c.T1437C:p.D479D	B	-	-	-	15	88.2	17	100.0	16	94.1	0.145	0.545	0.346
c.T4260C:p.N1420N	B	-	-	-	1	5.9	1	5.9	0	0.0	1.00	0.31	0.594
c.G6909A:p.L2303L	B	-	-	-	2	11.8	3	17.6	2	11.8	0.628	1.00	0.847
c.C5553T:p.S1851S	B	-	-	-	2	11.8	3	17.6	2	11.8	0.628	1.00	0.847
c.C5469T:p.A1823A	B	-	-	-	3	17.6	1	5.9	1	5.9	0.287	0.287	0.412
c.G3462C:p.R1154R	B	-	-	-	3	17.6	1	5.9	1	5.9	0.287	0.287	0.412
c.C4449T:p.C1483C	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.T255C:p.G85G	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C6808T:p.R2270W	-	D	D	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A4356G:p.K1452K	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C4376T:p.A1459V	VUS	D	B	-	0	0.0	0	0.0	2	11.8	NA	0.145	0.125
c.A5397G:p.E1799E	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C7279T:p.L2427L	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C4556T:p.A1519V	LP	D	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361

c.G6016T:p.V2006F	-	D	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A7256G:p.E2419G	-	D	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G1148A:p.S383N	B	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
TBC1D4													
c.G2455A:p.V819I	LB	T	B	-	12	70.6	16	94.1	16	94.1	0.072	0.072	0.071
c.T1611G:p.S537S	LB	-	-	-	5	29.4	9	52.9	5	29.4	0.163	1.00	0.261
c.G723C:p.G241G	LB	-	-	-	17	100.0	17	100.0	17	100.0	1.00	1.00	1.00
c.C84G:p.P28P	LB	-	-	-	10	58.8	8	47.1	13	76.5	0.492	0.271	0.21
c.T3824C:p.V1275A	LB	T	B	-	1	5.9	3	17.6	1	5.9	0.287	1.00	0.412
c.C2901T:p.L967L	LB	-	-	-	12	70.6	14	82.4	11	64.7	0.419	0.714	0.502
c.C606T:p.F202F	LB	-	-	-	3	17.6	1	5.9	2	11.8	0.287	0.628	0.567
c.C3440T:p.T1147M	LB	T	B	-	1	5.9	0	0.0	2	11.8	0.31	0.545	0.346
c.C302T:p.A101V	LB	T	B	-	1	5.9	2	11.8	2	11.8	0.545	0.545	0.801
c.G2324A:p.R775H	-	T	D	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G1902A:p.P634P	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G330A:p.T110T	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C1046G:p.S349W	-	D	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A2913T:p.G971G	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C3238T:p.P1080S	-	D	D	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A2254G:p.T752A	B	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
CACNA1E													
c.T2577A:p.D859E	-	T	B	-	4	23.5	2	11.8	2	11.8	0.368	0.368	0.553
c.G2992A:p.G998S	-	T	B	-	1	5.9	0	0.0	1	5.9	0.31	1.00	0.594
c.C3447T:p.I1149I	-	-	-	-	4	23.5	2	11.8	2	11.8	0.368	0.368	0.553
c.T4008C:p.H1336H	-	-	-	-	8	47.1	7	41.2	6	35.3	0.73	0.486	0.784
c.G5863A:p.A1955T	-	T	B	-	8	47.1	12	70.6	11	64.7	0.163	0.3	0.343
c.C5073T:p.N1691N	-	-	-	-	7	41.2	7	41.2	6	35.3	1.00	0.72	0.921
c.A750G:p.A250A	-	-	-	-	1	5.9	2	11.8	0	0.0	0.545	0.31	0.346
c.C6567T:p.S2189S	-	-	-	-	1	5.9	3	17.6	1	5.9	0.287	1.00	0.412
c.2137_2142del:p.T713_K714del	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C6536T:p.A2179V	-	T	B	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A1935G:p.A645A	LB	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C4905T:p.D1635D	B	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.A2706G:p.G902G	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.A3078G:p.P1026P	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G3362A:p.R1121H	-	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.C2260T:p.H754Y	-	T	B	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.G6869A:p.G2290E	-	D	P	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361

MNX1													
c.C444T;p.G148G	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.G981A;p.E327E	-	-	-	-	0	0.0	1	5.9	0	0.0	0.31	NA	0.361
c.C47A;p.A16D	-	T	B	-	0	0.0	2	11.8	0	0.0	0.145	NA	0.125
c.G357T;p.P119P	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361
c.T429C;p.P143P	-	-	-	-	0	0.0	0	0.0	1	5.9	NA	0.31	0.361

We further evaluated MODY patients individually and unveiled the presence of one or more possibly pathogenic, probably pathogenic, deleterious or variant with conflicting pathogenicity according to either ClinSig, SIFT, Polyphen, and ClinVar in 15 (88%) patients, and no pathogenic variants in 2 (12%) of them. Among the aforementioned 15 patients, a single variant was detected in three cases while the remaining twelve cases surprisingly presented two or more pathogenic variants, as up to five variants were detected in patients 1 and 6 (Table 4, Figure 1).

Table 4. Pathogenic/possibly/probably pathogenic, deleterious, or CIP variants in MODY 1-14 genes per MODY patient


Patient # Treatment	Pathogenic present	variants	ClinSig	SIFT	PolyPhen	Clin Var	Mody freq	T2DM freq	Healthy freq	P-val	Exeter score
Pt. 1	CEL c.C1226T;p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	0.0	<0.001	45.5
Insulin	CEL c.T2059G;p.S687A	-	Del.	Possibly Damaging	-	2 (11.8)	0.0	0.0	0.0	0.125	
	CEL c.G2065C;p.A689P	-	Del.	Probably Damaging	-	2 (11.8)	0.0	0.0	0.0	0.125	
	APPL1 c.A2099G;p.E700G	-	Del.	Benign	-	4 (23.5)	2 (11.8)	4 (23.5)	0.608		
	HNF1A c.A79C;p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92		
Pt 2. Insulin Metformin Glimepiride	HNF1A c.A79C;p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92		75.5
Pt. 3 Insulin Metformin	CEL c.C1226T;p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	0.0	<0.001	75.5

Dapagliflozin Liraglutide	ABCC8 c.G1720A:p.V574M	-	Tol.	Probably Damaging	-	1 (5.9)	0.0	0.0	0.361	
Pt. 4	GCK c.T668C:p.M223T	-	Del.	Benign	LP	1 (5.9)	0.0	0.0	0.361	75.5
Metformin	CEL c.C1226T:p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	
	BLK c.A974C:p.K325T	B/LB	Del.	Possibly Damaging	B	1 (5.9)	0.0	1 (5.9)	0.594	
	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 5 Metformin Linagliptin	No MODY pathogenic variants									45.5
Pt. 6	CEL c.C1226T:p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	62.4
Metformin Glimepiride	CEL c.T2059G:p.S687A	-	Del.	Possibly Damaging	-	2 (11.8)	0.0	0.0	0.125	
	CEL c.G2065C:p.A689P	-	Del.	Probably Damaging	-	2 (11.8)	0.0	0.0	0.125	
	CEL c.G1801C:p.A601P	-	Del.	Possibly Damaging	-	1 (5.9)	0.0	0.0	0.361	
	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 7 Semaglutide Pioglitazone Glimepiride	PAX4 c.G680A:p.R227Q	-	Del.	Probably Damaging	-	1 (5.9)	0.0	0.0	0.361	75.5
	KCNJ11 c.C540G:p.L180L	CIP	-	-	-	1 (5.9)	0.0	0.0	0.361	
Pt. 8 Diet and exercise	APPL1 c.A2099G:p.E700G	-	Del.	Benign	-	4 (23.5)	2 (11.8)	4 (23.5)	0.608	75.5
Pt. 9 Liraglutide Metformin Glimepiride	CEL c.C1226T:p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	35.8
	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 10	APPL1 c.A2099G:p.E700G	-	Del.	Benign	-	4 (23.5)	2 (11.8)	4 (23.5)	0.608	75.5
Metformin	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 11	CEL c.C1226T:p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	45.5
Insulin	CEL c.G41C:p.C14S	-	Del.	Possibly Damaging	-	1 (5.9)	0.0	0.0	0.361	
	CEL c.T1454C:p.I485T	B/LB	Del.	Probably Damaging	B	1 (5.9)	0.0	0.0	0.361	
	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 12 Insulin	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	75.5
Pt. 13 Insulin Linagliptin	CEL c.C1226T:p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	75.5
	HNF1A c.A79C:p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 14	CEL c.C1226T:p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	58
Dapagliflozin Metformin	CEL	Pathogenic	-	-	-	1 (5.9)	0.0	0.0	0.361	

Glimepiride		c.2032dupC;p.V681Rfs*6								
	HNF1A c.A79C;p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 15 Metformin Glimepiride Linagliptin Dapagliflozin	CEL c.C1226T;p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	75.5
	APPL1 c.A2099G;p.E700G	-	Del.	Benign	-	4 (23.5)	2 (11.8)	4 (23.5)	0.608	
Pt. 16 Metformin	HNF1A c.1137delT;p.V380Sfs*4	Pathogenic	-	-	P	1 (5.9)	0.0	0.0	0.361	75.5
	CEL c.C1226T;p.T409I	-	Del.	Probably Damaging	-	10 (58.9)	0.0	0.0	<0.001	
	HNF1A c.A79C;p.I27L	Benign	Tol.	Benign	CIP	11 (64.7)	11 (64.7)	10 (58.8)	0.92	
Pt. 17 Insulin	No MODY pathogenic variants									49.4

ClinSig: B=Benign, “-” = Unknown, B/LB= Benign/ Likely Benign, LB= Likely benign, CIP= Conflicting interpretation of pathogenicity, P= Pathogenic. SIFT: Tol= Tolerable; Del= deleterious, “-” = Unknown. PolyPhen: D=Probably damaging, P=Possibly damaging, B=benign, “-” = Unknown/Not reported. ClinVar: P=Pathogenic, LP=Likely Pathogenic, B=Benign, LB=Likely Benign, CIP=Conflicting interpretation of pathogenicity.

Figure 1. Clustered heatmap of genetic variants for MODY and T2DM detected across groups



BMI=Body Mass Index; under treatment goals criteria was defined as an HbA1C equal or lower than 7.0%.

Regarding T2DM predisposing genes, a total of 38 variants (including HNF1A) were detected among all subjects. Two benign HNF1A variants yielded statistically significant differences across groups (c.G864C:p.G288G and c.G1545A:p.T515T), the first having a prevalence of 52.9, 82.4 and 88.2% among MODY, T2DM and healthy controls, while the second was present in 0% of patients with MODY, 17.6% of patients with T2DM, and 41.2% of healthy controls. No other significant differences were found in the rest of T2DM genes.

WES mutational analysis

Upon WES mutational analysis of all included subjects, the three groups exhibited similarities in the overall distribution of variants. However, each group presented specific genes with unique variants. MODY, T2DM, and healthy controls displayed an average range of 11,057 to 11,822 variants, with missense mutations being the most prevalent type. Among these, transitions (C>T and T>C) were the most common changes. The top mutated genes, including *MUC4*, *MUC12*, *MUC16*, and *HLA-A*, were shared across the groups. To identify differences in variant distribution between groups, we conducted a Fisher's exact test on 2x2 contingency tables, revealing several genes with differential variants.

We describe several genes that exhibited significant differences among the groups. Considering a cutoff value of an adjusted $p < 0.01$, we identified 53 genes when comparing MODY versus non-MODY cases, 30 genes in MODY versus T2DM, 30 genes in MODY versus healthy controls, and none in the comparison of T2DM versus healthy controls. When focusing exclusively on high-impact variants, we detected 21 significant genes in MODY versus non-MODY, 17 in MODY versus T2DM, 16 in MODY versus healthy, and none in T2DM versus healthy.

When comparing all exonic variants in the MODY versus the non-MODY group (T2DM + healthy controls), *ABC7-42389800N19.1*, *ASAH2*, *OR2A42*, and *RIMBP3C* harbored variants exclusive to the non-MODY group, while *KCNJ12* and *OR2A1* exhibited variants exclusively in MODY, as shown in Figure 2,3 and Table 5. Thus, *KCNJ12* and *OR2A1* presented multihit and missense variants in 100% of MODY cases, while no healthy or T2DM patients harbored such variants. When comparing MODY to T2DM, the same set of exclusive genes was observed. However, in the MODY versus healthy comparison, *CLEC18B* showed variants exclusively present in MODY, while only present in 12% of T2DM patients. Notably, no significant variants were detected between the T2DM and healthy groups.

Other genes presented statistically significant differences across MODY and non-MODY groups, without being exclusive to any. Genes such as *RIMBP3*, *TRIM49C*, *CLEC18B*, *OR2T5*, *PEX5*, *AQP12B*, *OR51A4*, *SYT15*, *TRIM64*, *GSTT2B*, *SUSD2*, *TPTE*, and *ZNF814* were enriched in MODY patients, while *NBPF6*, *PGA3*, *GOLGA8N*, *PABPC1*, *PABPC3*, *CNTNAP3B*, *POTEM*, and *SPIN2A* in non-MODY cases (Figure 2,3 and Table 5).

Figure 2. Frequency of overall genetic variants in MODY and T2DM patients





Figure 3. Frequency of overall genetic variants in MODY and healthy subjects



We further identified high-impact variants that distinguished between groups. In the MODY versus non-MODY comparison, splice-site variants in *ABC7-42389800N19.1* and multiple high-impact variants in *MUC6* were exclusive to the non-MODY group, while *MAP2K3* harbored nonsense mutations exclusively in MODY (Figure 4,5,6 and Table 5). In the MODY versus healthy comparison, *OR8U1* exhibited multiple high-impact variants, which were exclusive to the healthy group. No significant variants were identified between T2DM and healthy groups. Finally, we found significant differences in the frequency of high impact genetic variants when comparing the MODY group versus the T2DM and healthy groups in additional genes to *MAP2K3* such as *PEX5*, *KMT2C*, and *ZNF717* (all with a p-value <0.01 in both comparisons), while *TPTE*, *DHRS4L2*, and *IL32* genes presented high impact variants in the MODY patients with significant differences (p<0.05) when compared to the T2DM group but not versus healthy controls (Figure 4,5,6 and Table 5). Specifically, the

detected variants in *MAP2K3* include c.281G>T (p.Arg94Leu), c.286C>T (p.Arg96Trp), c.304C>T (p.Gln102Ter) (all three found in 100% of MODY patients, while 0% of non-MODY), and variant c.118C>A (p.Pro40Thr), found exclusively in 94% of MODY cases. Regarding *PEX5* gene, the splicing variant (c.210+77_210+121delCAGCCTCTGAGGCAGTGAGTGTCTTGAGGTGGAAAGCCCAGG TG) was identified in 94% of MODY cases exclusively. c.2447dupA (p.Tyr816Ter) variant in *KMT2C* was found in 76% of MODY cases exclusively. In the *IL32* gene, the frameshift variant c.652dupG (p.Asp218GlyfsTer12) and the missense variant c.653A>G (p.Asp218Gly) were found in 47% of MODY cases.

Conversely, genes that frequently presented high impact variants in T2DM and healthy controls while were rather infrequent among MODY patients include the previously mentioned *ABC7* and *MUC6*, *PLIN4*, *OR8U1*, *NBPF11*, *PABPC3*, *RBMX*, *LILRA6*, *PABPC1*, and *ARHGEF5*, all of which presented significant differences in both groups when compared to MODY at a $p < 0.01$ (Table 5).

Figure 4. Frequency of high impact genetic variants in MODY and T2DM patients




Figure 5. Frequency of high impact genetic variants in MODY and healthy subjects




Table 5. Genes with statistically significant differences across MODY versus T2DM and healthy groups


Genes	MODY vs T2DM			MODY vs Healthy		
	MODY (n=17)	T2DM (n=17)	Adj. P-val	MODY (n=17)	Healthy (n=17)	Adj. P-val
Genes in MODY group (overall)						
KCNJ12	17	0	<0.0001	17	0	<0.0001
OR2A1	17	0	<0.0001	17	0	<0.0001
RIMBP3	16	0	<0.0001	16	1	0.00015
TRIM49C	16	0	<0.0001	16	0	<0.0001
CLEC18B	17	2	<0.0001	17	0	<0.0001
OR2T5	16	1	0.00013	16	0	<0.0001
PEX5	16	1	0.00013	16	1	0.00015
AQP12B	17	3	0.00040	17	5	0.00596
OR51A4	17	3	0.00040	17	4	0.00193
SYT15	14	0	0.00040	14	0	0.00041
TRIM64	14	0	0.00040	14	0	0.00041
RIMBP3B	16	2	0.00083	16	5	0.04172
GSTT2B	12	0	0.00587	12	0	0.00596
LAIR2	17	5	0.00587	17	6	0.01593
SUSD2	17	5	0.00587	17	3	0.00041
TPTE	17	5	0.00587	17	3	0.00041
ZNF322	12	0	0.00587	12	2	0.154
ZNF814	17	5	0.00587	17	3	0.00041
IGHV1-69	15	3	0.01732	15	2	0.00554
IGKV1D-17	11	0	0.01732	11	0	0.01593
TNFRSF10C	17	6	0.01732	17	8	0.122
PRAMEF7	12	1	0.04415	12	0	0.00596
KMT2C	15	8	1.00	15	3	0.01593
CTAGE8	11	1	0.113	11	0	0.01593
GOLGA6L10	10	0	0.051	10	0	0.04605
IGHV3-30	10	0	0.051	10	0	0.04605
KRTAP4-3	10	2	0.727	10	0	0.04605
Genes in non-MODY (T2DM + healthy) groups (overall)						
ABC7-42389800N19.1	0	17	<0.0001	0	17	<0.0001
ASAH2	0	17	<0.0001	0	17	<0.0001
OR2A42	0	17	<0.0001	0	17	<0.0001
RIMBP3C	0	17	<0.0001	0	17	<0.0001
NBPF6	1	17	<0.0001	1	15	0.00084

PGA3	0	16	<0.0001	0	15	0.00011
GOLGA8N	2	17	<0.0001	2	17	0.00011
PABPC1	0	15	<0.0001	0	14	0.00041
PABPC3	1	14	0.004686	1	14	0.00454
CNTNAP3B	5	17	0.005874	5	17	0.00596
POTEM	5	17	0.005874	5	17	0.00596
SPIN2A	5	17	0.005874	5	17	0.00596
PLEKHH3	1	13	0.014888	1	13	0.01418
CBWD1	3	15	0.017321	3	9	1.00
KRTAP2-1	3	15	0.017321	3	7	1.00
PRAMEF8	2	14	0.017321	2	14	0.01593
GOLGA6B	6	17	0.017321	6	17	0.01593
TBC1D3K	0	11	0.017321	0	12	0.00596
OR4F17	1	12	0.044153	1	10	0.249
GOLGA8T	1	10	0.267	1	13	0.01418
POTEH	4	15	0.06	4	16	0.01418
DEFB104A	3	13	0.18	3	15	0.01593
RBMX	3	14	0.065	3	15	0.01593
PRR23D2	0	6	0.88	0	11	0.01593
TRIM49	6	15	0.39	6	17	0.01593
IGKV6-21	0	8	0.27	0	10	0.04605
RUNX1	0	7	0.522	0	10	0.04605
USP17L18	7	16	0.267	7	17	0.04605
Genes in MODY group (high impact)						
MAP2K3	17	0	<0.0001	17	0	<0.0001
PEX5	16	0	<0.0001	16	0	<0.0001
KMT2C	13	0	0.00019	13	0	0.0002
ZNF717	13	0	0.00019	13	1	0.0016
DHRS4L2	8	0	0.046	8	0	0.0503
IL32	8	0	0.046	8	0	0.0503
TPTE	8	0	0.046	8	0	0.0503
Genes in non-MODY (T2DM + healthy) groups (high impact)						
ABC7-42389800N19.1	0	17	<0.0001	0	17	<0.0001
MUC6	0	17	<0.0001	0	17	<0.0001
PLIN4	0	16	<0.0001	0	12	0.0007
OR8U1	0	15	<0.0001	0	17	<0.0001
NBPF11	0	14	<0.0001	0	11	0.002
PABPC3	0	14	<0.0001	0	14	<0.0001
LILRA6	0	12	0.00071	0	12	0.0007
PABPC1	0	12	0.00071	0	13	0.0002
RBMX	1	13	0.00172	1	14	0.0004

ARHGEF5	1	12	0.0062	1	14	0.0004
AQP12A	0	10	0.006	0	5	0.3
OR4F5	0	10	0.006	0	7	0.11
TCP10	0	10	0.006	0	6	0.18
ZXDA	4	14	0.0328	4	8	0.059
WASHC1	1	10	0.046	1	12	0.0005

Figure 6. Lollipop diagrams of MODY enriched genes in the Mexican population contrasting variant frequency versus non-MODY group. .

Upper row MAP2K3 (left), PEX5 (right); second row ZNF717 (left), KMT2C (right); third row KCNJ12 (left), OR2A1 (right); lower row CLEC18B (left), OR2T5 (right).



Discussion

We characterized the genomic landscape of Mexican MODY patients by describing the variant frequency of MODY and T2DM predisposing genes across three cohorts of Mexican healthy, T2DM, and MODY subjects and proposed a set of novel candidate genes that displayed significant differences across groups in a Latino population.

Our findings indicate that although several MODY 1-14 gene variants are present in Mexican MODY cases, they do not differ significantly from T2DM and healthy Mexican individuals in most cases, as only 5% of MODY-known variants displayed significant differences among non-MODY subjects. The only pathogenic/damaging genetic variant that presented statistical significant differences with an increased frequency in MODY patients was c.C1226T:p.T409I in *CEL* gene (deleterious by SIFT and probably damaging by PolyPhen), detected in 58.9% (10/17) of MODY patients, while was present in 0% of T2DM and healthy subjects. Other benign variants that presented an increased frequency in MODY subjects when compared to the other two groups include c.C2064G:p.G688G in *CEL* gene, and c.C1683T:p.H561H in the *ABCC8* gene, which was significantly more frequent in MODY when comparing with T2DM patients but not in healthy subjects. In the *HNF4A* gene, the variant c.C341T:p.T114I (likely benign) was significantly more frequent in MODY than in healthy subjects, but not T2DM.

Other possibly/probably pathogenic, deleterious, pathogenic or CIP variants that presented non-statistically significant differences between groups that were detected in MODY cases include *HNF1A* c.A79C:p.I27L, which presented a similar frequency among the three groups, ranging from 58-64%; *APPL1* c.A2099G:p.E700G, detected in 23.5% of MODY patients; c.T2059G:p.S687A, and c.G2065C:p.A689P in *CEL* gene, found in 11.7% of MODY cases and absent in all T2DM and healthy controls, and other variants found in single MODY patients and no controls such as *GCK* c.T668C:p.M223T; *HNF1A* c.1137delT:p.V380Sfs*4; *CEL* c.G1801C:p.A601P, c.G41C:p.C14S, c.T1454C:p.I485T, c.c.2032dupC:p.V681Rfs*6; *PAX 4* c.G680A:p.R227Q.

Variants in T2DM-predisposing genes that exhibited significant differences favoring an increased frequency in T2DM and healthy groups include: *HNF1A* c.G864C:p.G288G and c.G1545A:p.T515T (both benign for MODY and VUS for T2DM according to ClinVar), and *CEL* c.C1710T:p.P570P (likely benign through ClinSig).

When analyzing MODY cases individually, 12% of MODY patients did not harbor any variant of risk for classical MODY 1-14 genes, 18% of cases presented a single possibly/probably pathogenic, deleterious, pathogenic or CIP variant, and 70% of patients presented two or more concomitant genetic variants with the aforementioned clinical impact. However, if we do not consider CIP variants, the frequency of MODY patients without a detected MODY variant rises up to 24%.

Our findings indicate that contrary to the existing literature MODY does not always behave as a monogenic disease in a Latino population, as concomitant pathogenic, possibly/probably damaging, deleterious or CIP variants were detected in single cases. Thus, MODY is a polygenic disease in several cases, which leads to a paradigm shift in the understanding of this disease in non-caucasian populations.

The association of 1) no MODY-known pathogenic, possibly/probably damaging, deleterious or CIP variants in 12-24% of our MODY patients upon individual analysis, 2) finding only one

SIFT-deleterious and PolyPhen-probably damaging variant that yielded statistically significant differences among groups, and 3) the fact that MODY 1-14 genes description is based on caucasian populations, lead us to investigate the presence of other genetic variants that could explain MODY genetic landscape in our population. This knowledge gap is supported by several authors who have pointed to the existence of other genes involved in early onset of diabetes in non-caucasian populations, and the need of WES studies to elucidate new genes involved in glycaemic regulation [10,11,22,23].

Additional efforts conducted worldwide to better characterize MODY have pointed out other genes and variants linked to this disease. Patel et al. reported the involvement of RFX6 variants in a Finnish cohort of MODY cases, which has also been documented in case reports [24,25]. We intentionally searched all RFX6 variants and found a non-statistically significant increased frequency of several variants among MODY cases, being all benign or likely benign through ClinSig database. Regarding the enrichment of p.His293Leu variant reported by Patel et al within Finnish MODY cases, we did not detect the aforementioned variant in any of our patients or controls [24]. Additionally, other authors such as Mohan et al. evaluated variants of known-MODY and other genes such as *WFS1*, *NKX6-1*, and *AKT2* in South Indian patients with MODY (Table 3) [26]. Moreover, Jakiel et al. proposed a set of candidate genes including *MTOR*, *TBC1D4*, *CACNA1E*, and *MNX1* in Polish MODY patients without a genetic diagnosis, and Simate et al. described the causal role of *PCBD1* mutations in early-onset non autoimmune diabetes [27,28]. We intentionally searched for genetic variants in all of the aforementioned genes and did not find statistically significant different frequencies across groups in our studied population (Table 3).

In the context of a highly heterogeneous genetic disease where the current evidence has been predominantly generated upon caucasian populations, we propose a novel set of candidate genes in a Latino MODY population. Considering the cutoff value of an adjusted $p < 0.01$, we propose a set of 15 candidate genes (*KCNJ2*, *OR2A1*, *RIMBP3*, *TRIM49C*, *CLEC18B*, *OR2T5*, *PEX5*, *AQP12B*, *OR51A4*, *SYT15*, *TRIM64*, *GSTT2B*, *SUSD2*, *TPTE*, *ZNF814*) which are significantly enriched in Mexican MODY patients and not in T2DM and healthy subjects belonging to the same population, and 12 genes significantly enriched in Mexican T2DM and healthy groups, while not in MODY cases (*ABC7*, *ASAH2*, *OR2A42*, *RIMBP3C*, *NBPF6*, *PGA3*, *GOLGA8N*, *PABPC1*, *PABPC3*, *CNTNAP3B*, *POTEM*, *SPIN2A*).

Upon analysis of high impact variants exclusively and considering a cutoff value of an adjusted $p < 0.01$, we propose a set of 4 genes (*MAP2K3*, *PEX5*, *KMT2C*, and *ZNF717*) enriched in the MODY population when compared to both T2DM and healthy subjects and 10 genes (*ABC7*, *MUC6*, *PLIN4*, *OR8U1*, *NBPF11*, *PABPC3*, *RBMX*, *LILRA6*, *PABPC1*, and *ARHGEF5*) enriched in both Mexican T2DM and healthy groups.

Additionally, *TPTE*, *DHRS4L2*, and *IL32* genes presented high impact variants in the MODY patients with statistically significant differences when compared to the T2DM group. Several of the proposed genes have implications on glucose metabolism and beta-cell function. In-depth understanding and analysis of the possible association of each candidate gene represents a key aspect in which our findings may contribute to the understanding of MODY pathophysiology.

The MAP2K3 gene encodes for a protein that belongs to a MAP kinase kinase family, which mediates MAP signaling kinase pathway through phosphorylation of MAP14/p38-MAPK [29]. In glycemic regulation, MAP2K3 activity is enhanced by insulin, being necessary for the expression of glucose transporters [30]. Fujishiro et al. described the role of p38-MAPK and MAPK6 glucose transport regulation, describing that p38-MAPK activation leads to downregulation of insulin-induced glucose uptake via GLUT4 [30], which could also explain insulin resistance states in cellular stress conditions. Li et al also examined the effect of AMPK (AMP-activated protein kinase) in p38-MAPK activation, finding p38-MAPK involvement in glucose transport, while its inhibition reduced glucose uptake and GLUT 4 translocation [31]. Other authors have described altered p38-MAPK activity in skeletal muscle, adipose tissue among T2DM patients and in diabetic nephropathy [32,33].

Next, PEX5 gene plays a crucial role in peroxisomal protein import, as its product binds to the C-terminal PTS1-type tripeptide peroxisomal targeting signal [29]. PEX5 delivers folded proteins from the cytosol into peroxisomes, translocating them across the membrane and then returning to the cytosol [34]. Peroxisomes are ubiquitous organelles deeply involved in lipid metabolism, and beta-cell homeostasis. Baboota et al demonstrated in a murine model impaired insulin secretion, and glucose intolerance in Rip-Pex5 *-/-* mice due a decrease in the density of mature insulin granules, degenerative features of mitochondria and accumulation of vacuole-like structures, which have also been identified in beta-cells from patients with T2DM [35]. Peroxisome proliferator-activated receptor(PPAR) alpha agonists have also been demonstrated to confer protection to beta-cells against fatty acids such as palmitate [36]. Defects in PEX genes and peroxisome biogenesis impact multiple systems, as found in Zellweger spectrum disorders, characterized by lipid metabolism alterations, distinct craniofacial malformations, hepatomegaly, renal cysts, seizures, and profound hypotonia [37,38].

The KMT2C gene (lysine methyltransferase 2C) encodes for a protein with high histone methylation activity and involvement in transcriptional activation [29]. Lysine methylation plays a key role in glucose and lipid metabolism, as analysis of human insulin promoters have identified various CpG sites in upstream regions to the transcription start site of insulin and demethylation is considered to play a crucial role in beta-cell maturation and tissue-specific insulin gene expression [39,40]. Islets in T2DM patients present increased DNA methylation and decreased expression of several key genes, existing impaired insulin secretion [40]. Moreover, methylation regulates rate-limiting enzymes in several metabolic pathways, being altered methylation patterns frequently encountered in T2DM [41].

Another gene with high impact variants predominantly found in MODY with not fully understood implications in glucose metabolism is the ZNF717 gene. Zinc-finger proteins are involved in transcriptional regulation and play key roles in various cellular functions including cell proliferation, differentiation and apoptosis [29,42]. Several ZNF family genes are considered to have a key role in diabetes, such as *GLIS3*, which regulates insulin expression through binding to the *INS* promoter and regulation of beta-cell transcription factors, while *GLIS3* mutations are considered a cause of neonatal diabetes [42]. Deficiency in other members of the Zinc finger protein family such as the ZFP251 have been discovered to induce glucose metabolism impairment through adipocyte hypertrophy in mice [43]. ZFP407

regulates insulin-stimulated glucose uptake in adipocytes via GLUT4, and is involved in PPAR gamma regulation, which induces GLUT4 expression and is the target of rosiglitazone [44].

We described enrichment in other genes such as *DHRS4L2* (Dehydrogenase/Reductase 4 Like 2), which encodes for a member of the short chain dehydrogenase reductase family [29]. Regarding the *IL32* gene, increased IL-32 plasma levels have been documented in Mexican subjects with overweight and obesity, while have been also associated with T2DM in a middle-eastern population [45,46]. *TPTE* gene (transmembrane phosphatase with tensin homology), plays a key role in signal transduction pathways in endocrine and spermatogenic functions in the testis [29]. The specific association and mechanisms of the above mentioned genes in glucose metabolism remain to be elucidated through further research.

The proposed genes also include *KCNJ12*, which similarly to *KCNJ11* (MODY 13 causal gene) encodes for a Potassium Inwardly Rectifying Channel (Kir 2.2) [29]. It also contributes to the cardiac inwardly rectifying potassium current (IK1) that stabilizes resting membrane potential, and is responsible for shaping the initial depolarization and final repolarization of the action potential [47]. Mutations in this gene have been related with colorectal carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma and skin cancer, as well as with dilated cardiomyopathy [48]. In cancer oncogenesis, *KCNJ12* acts as a target for miR-132-3p to modulate the AKT signaling pathway, also involved in the glucose metabolism by increasing GLUT-1 and GLUT-4 translocation [49].

Other proposed candidate genes are reported in literature for their role in metabolic disorders such as *OR2A1* (Olfactory Receptor Family 2 Subfamily A Member 1), which was found differentially expressed in T2DM and obesity [50]. Moreover, Olfactory Receptors (OR) play key roles in glucose metabolism, as participates in gluconeogenesis in the liver and is expressed in pancreatic islets, regulating insulin secretion in an autocrine manner and involving in islet homeostasis [51,52]. *TRIM64* large copy-number variation enrichment was reported by Wang et al. in patients with moderate to extreme obesity when compared to control subjects [53].

WASHC1 gene encodes for the Wiskott-Aldrich Syndrome complex subunit 1. WAS protein superfamilies are involved in endosomal receptor trafficking via Arp2/3 complex activation [54]. *WASH* is highly expressed in both human and murine pancreatic islets. Ding et al. demonstrated through a conditional knockout (cKO) in murine pancreatic beta-cells the presence of impaired glucose clearance and significantly lower insulin release in cKO mice. Another fundamental implication of *WASH* in glucose metabolism is the fact that GLUT2 protein levels decrease in the absence of *WASH* [54].

Aquaporins (AQP) are a family of membrane proteins that serve as transmembrane water channels [55]. AQP are directly involved in insulin resistance and T2DM, lipid metabolism, and oxidative stress regulation [55]. *AQP7* expression has been demonstrated in pancreatic beta-cells and *AQP7* knockout mice display increased insulin secretion, augmented intracellular triacylglycerol concentrations, and reduced beta-cell mass [56]. Additionally, *AQP7* protein expression is increased in obese men with T2DM [56]. Further research is

required to elucidate if *AQP12A* gene plays a role in glucose metabolism and insulin secretion.

The *ABC7* gene belongs to the adenosine triphosphate-binding cassette (ABC) transporter superfamily, and encodes for a protein responsible for the transport across extra- and intra-cellular membranes [29, 57]. In glucose metabolism, the concentration of cholesterol in beta-cells is considered a determinant for islet dysfunction, being regulated by two ABC superfamily members [58]. *ABCA1* deficiency in beta-cells resulted in impaired insulin secretion in murine models, while some variants are associated with increased risk of ischemic heart disease [59,60]. Nevertheless, *ABCA1* genetic variants are not considered to increase T2DM risk in the general population [58]. Furthermore, *ABCC8* (ATP-binding cassette transporter sub-family C member 8) encodes the sulfonylurea receptor 1 (SUR1), being its mutations associated with MODY type 12 [61,62]. SUR1 regulates the activity of the potassium channel in pancreatic beta-cells membrane. Activating SUR1 mutations cause decreased insulin secretion [62].

The *MUC6* gene encodes for a member of the mucin protein family, which are high molecular weight glycoproteins produced by several epithelial tissues [29]. Pujar et al. reported MUC6 enrichment as a candidate biomarker for T1DM, being closely related to disease progression and occurrence of hypertension [63]. The *MUC6* gene is physiologically expressed in pancreatic tissue, and has been related to pancreatic neoplasia [64]. Moreover, MUC6 has been linked to distinct types of diabetes and immune regulation, authors as Mousa et al. have pointed out the need to elucidate the association of *MUC6* with diabetes [65].

To the best of our knowledge, this study represents the first effort to characterize the genomic landscape of Mexican MODY patients through WES and to propose a set of candidate genes involved in MODY diagnosis, which can serve as potential biomarkers to better diagnose monogenic diabetes in Latino populations. The strengths of our study include conducting WES as part of the methodology unlike other studies of MODY using panels with limited genes and the comparison of our findings in MODY patients with healthy controls and T2DM belonging to the same Latino population. Limitations of our study include the need for external validation of the novel candidate genes, lack of non-coding region analysis, and lack of genetic evaluation of MODY patient relatives.

Future perspectives on this line of research include performing external validation of the candidate genes, evaluation of the genomic landscape in Mexican pediatric MODY patients, genotype-phenotype association analysis among cases, and development of AI-assisted models to better predict and combine biomarkers for the diagnosis of MODY. The latter could help incorporate new tools into clinical practice in order to achieve a correct diagnosis of patients with MODY in the context of a Latino population.

Conclusion

MODY presents as a genetically heterogeneous disease in the Mexican population. Despite that MODY 1-14 genetic variants are frequent among Mexican MODY patients, T2DM and

healthy controls present similar frequency rates in most of them. In many cases, we identified the presence of concomitant variants among Mexican MODY cases, indicating that MODY behaves as a polygenic disease in some patients. Moreover, we proposed a novel set of candidate genes that presented significant enrichment in Mexican MODY patients and could be associated with MODY pathogenesis and diagnosis in the context of Latino populations.

Conflicts of interest: The authors have no conflicts of interest to declare.

References

- 1.- Fajans SS, Bell GI, Polonsky KS. Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young. *N Engl J Med*. 2001 Sep 27;345(13):971–80.
2. Peixoto-Barbosa R, Reis AF, Giuffrida FMA. Update on clinical screening of maturity-onset diabetes of the young (MODY). *Diabetol Metab Syndr*. 2020 Dec;12(1):50.
3. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). *BMJ*. 2011 Oct 19;343(oct19 3):d6044–d6044.
4. Nkonge KM, Nkonge DK, Nkonge TN. The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY). *Clin Diabetes Endocrinol*. 2020 Dec;6(1):20.
5. Breidbart E, Deng L, Lanzano P, Fan X, Guo J, Leibel RL, et al. Frequency and characterization of mutations in genes in a large cohort of patients referred to MODY registry. *Journal of Pediatric Endocrinology and Metabolism*. 2021 May 26;34(5):633–8.
6. Kavvoura FK, Owen KR. Maturity onset diabetes of the young: clinical characteristics, diagnosis and management. *Pediatr Endocrinol Rev*. 2012 Jan;10(2):234–42.
7. Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, et al. Prevalence, Characteristics and Clinical Diagnosis of Maturity Onset Diabetes of the Young Due to Mutations in HNF1A, HNF4A, and Glucokinase: Results From the SEARCH for Diabetes in Youth. *The Journal of Clinical Endocrinology & Metabolism*. 2013 Oct;98(10):4055–62.
8. Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, et al. Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young. *Diabetes Care*. 2012 Jun 1;35(6):1206–12.
9. Zhao J, Chen Y, Ma F, Shu H, Zheng L, Liu Y, et al. MODY Probability Calculator Is Suitable for MODY Screening in China: A Population-based Study. *Journal of the Endocrine Society*. 2024 Mar 12;8(5):bvae047.

10. Rafique I, Mir A, Saqib MAN, Naeem M, Marchand L, Polychronakos C. Causal variants in Maturity Onset Diabetes of the Young (MODY) – A systematic review. *BMC Endocr Disord*. 2021 Dec;21(1):223.
11. Al-Kandari H, Al-Abdulrazzaq D, Davidsson L, Nizam R, Jacob S, Melhem M, et al. Identification of Maturity-Onset-Diabetes of the Young (MODY) mutations in a country where diabetes is endemic. *Sci Rep*. 2021 Aug 9;11(1):16060.
12. Furuzawa GK, Giuffrida FMA, Oliveira CSV, Chacra AR, Dib SA, Reis AF. Low prevalence of MODY2 and MODY3 mutations in Brazilian individuals with clinical MODY phenotype. *Diabetes Research and Clinical Practice*. 2008 Sep;81(3):e12–4.
13. Maraschin JDF, Kannengiesser C, Murussi N, Campagnolo N, Canani LH, Gross JL, et al. HNF1 α mutations are present in half of clinically defined MODY patients in South-Brazilian individuals. *Arq Bras Endocrinol Metab*. 2008 Nov;52(8):1326–31.
14. Giuffrida FMA, Moises RS, Weinert LS, Calliari LE, Manna TD, Dotto RP, et al. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data. *Diabetes Research and Clinical Practice*. 2017 Jan;123:134–42.
15. Sampathkumar G, Valiyaparambil PP, Kumar H, Bhavani N, Nair V, Menon U, et al. Low genetic confirmation rate in South Indian subjects with a clinical diagnosis of maturity-onset diabetes of the young (MODY) who underwent targeted next-generation sequencing for 13 genes. *J Endocrinol Invest*. 2022 Mar;45(3):607–15.
16. Srinivasan S, Chen L, Todd J, Divers J, Gidding S, Chernausek S, et al. The First Genome-Wide Association Study for Type 2 Diabetes in Youth: The Progress in Diabetes Genetics in Youth (ProDiGY) Consortium. *Diabetes*. 2021 Apr 1;70(4):996–1005.
17. Palmer ND, Goodarzi MO, Langefeld CD, Wang N, Guo X, Taylor KD, et al. Genetic Variants Associated With Quantitative Glucose Homeostasis Traits Translate to Type 2 Diabetes in Mexican Americans: The GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium. *Diabetes*. 2015 May 1;64(5):1853–66.
18. Estrada K, Aukrust I, Bjørkhaug L, Burt NP, Mercader JM, García-Ortiz H, et al. Association of a Low-Frequency Variant in HNF1A With Type 2 Diabetes in a Latino Population. *JAMA*. 2014 Jun 11;311(22):2305.
19. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. *Salud Publica Mex*. 2023 Jun 13;65:s163–8.
20. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. *Genome Biol*. 2016 Dec;17(1):122.

21. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. *Genome Res.* 2018 Nov;28(11):1747–56.
22. Yalçın Çapan Ö, Aydın N, Yılmaz T, Berber E. Whole exome sequencing reveals novel candidate gene variants for MODY. *Clinica Chimica Acta.* 2020 Nov;510:97–104.
23. Zhong L, Zhao Z, Hu Q, Li Y, Zhao W, Li C, et al. Identification of Maturity-Onset Diabetes of the Young Caused by Mutation in FOXM1 via Whole-Exome Sequencing in Northern China. *Front Endocrinol.* 2021 Feb 9;11:534362.
24. Patel KA, Kettunen J, Laakso M, Stančáková A, Laver TW, Colclough K, et al. Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance. *Nat Commun.* 2017 Oct 12;8(1):888.
25. Imaki S, Iizuka K, Horikawa Y, Yasuda M, Kubota S, Kato T, et al. A novel RFX6 heterozygous mutation (p.R652X) in maturity-onset diabetes mellitus: A case report. *J of Diabetes Invest.* 2021 Oct;12(10):1914–8.
26. Mohan V, Radha V, Nguyen TT, Stawiski EW, Pahuja KB, Goldstein LD, et al. Comprehensive genomic analysis identifies pathogenic variants in maturity-onset diabetes of the young (MODY) patients in South India. *BMC Med Genet.* 2018 Dec;19(1):22.
27. Jakiel P, Gadzalska K, Juścińska E, Gorzałdek M, Płoszaj T, Skoczylas S, et al. Identification of rare variants in candidate genes associated with monogenic diabetes in polish mody-x patients. *J Diabetes Metab Disord.* 2023 Oct 13;23(1):545–54.
28. Simaite D, Kofent J, Gong M, Rüschenndorf F, Jia S, Arn P, et al. Recessive Mutations in PCBD1 Cause a New Type of Early-Onset Diabetes. *Diabetes.* 2014 Oct 1;63(10):3557–64.
29. Sayers EW, Bolton EE, Brister JR, Canese K, Chan J, Comeau DC, et al. Database resources of the national center for biotechnology information. *Nucleic Acids Research.* 2022 Jan 7;50(D1):D20–6.
30. Fujishiro M, Gotoh Y, Katagiri H, Sakoda H, Ogihara T, Anai M, et al. MKK6/3 and p38 MAPK Pathway Activation Is Not Necessary for Insulin-induced Glucose Uptake but Regulates Glucose Transporter Expression. *Journal of Biological Chemistry.* 2001 Jan;276(23):19800–6.
31. Li J, Miller EJ, Ninomiya-Tsuji J, Russell RR, Young LH. AMP-Activated Protein Kinase Activates p38 Mitogen-Activated Protein Kinase by Increasing Recruitment of p38 MAPK to TAB1 in the Ischemic Heart. *Circulation Research.* 2005 Oct 28;97(9):872–9.
32. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC, et al. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. *Diabetologia.* 2004 Jul;47(7):1210–22.

33. Koistinen HA, Chibalin AV, Zierath JR. Aberrant p38 mitogen-activated protein kinase signalling in skeletal muscle from Type 2 diabetic patients. *Diabetologia*. 2003 Oct 1;46(10):1324–8.
34. Skowrya ML, Rapoport TA. PEX5 translocation into and out of peroxisomes drives matrix protein import. *Molecular Cell*. 2022 Sep;82(17):3209-3225.e7.
35. Baboota RK, Shinde AB, Lemaire K, Fransen M, Vinckier S, Van Veldhoven PP, et al. Functional peroxisomes are required for β -cell integrity in mice. *Molecular Metabolism*. 2019 Apr;22:71–83.
36. Hellemans K, Kerckhofs K, Hannaert J, Martens G, Van Veldhoven P, Pipeleers D. Peroxisome proliferator-activated receptor α -retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. *The FEBS Journal*. 2007 Dec;274(23):6094–105.
37. Wangler MF, Hubert L, Donti TR, Ventura MJ, Miller MJ, Braverman N, et al. A metabolomic map of Zellweger spectrum disorders reveals novel disease biomarkers. *Genetics in Medicine*. 2018 Oct;20(10):1274–83.
38. Aubourg P, Robain O, Rocchiccioli F, Dancea S, Scotto J. The cerebro-hepato-renal (Zellweger) syndrome: Lamellar lipid profiles in adrenocortical, hepatic mesenchymal, astrocyte cells and increased levels of very long chain fatty acids and phytanic acid in the plasma. *Journal of the Neurological Sciences*. 1985 May;69(1–2):9–25.
39. Kuroda A, Rauch TA, Todorov I, Ku HT, Al-Abdullah IH, Kandeel F, et al. Insulin Gene Expression Is Regulated by DNA Methylation. Maedler K, editor. *PLoS ONE*. 2009 Sep 9;4(9):e6953.
40. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. *Cell Metabolism*. 2019 May;29(5):1028–44.
41. Kowluru RA, Mohammad G. Epigenetic modifications in diabetes. *Metabolism*. 2022 Jan;126:154920.
42. Cassandri M, Smirnov A, Novelli F, Pitolli C, Agostini M, Malewicz M, et al. Zinc-finger proteins in health and disease. *Cell Death Discov*. 2017 Nov 13;3(1):17071.
43. Kim E, Ham SA, Hwang JS, Won JP, Lee HG, Hur J, et al. Zinc finger protein 251 deficiency impairs glucose metabolism by inducing adipocyte hypertrophy. *Molecular and Cellular Endocrinology*. 2023 Feb;562:111838.
44. Buchner DA, Charrier A, Srinivasan E, Wang L, Paulsen MT, Ljungman M, et al. Zinc Finger Protein 407 (ZFP407) Regulates Insulin-stimulated Glucose Uptake and Glucose Transporter 4 (Glut4) mRNA. *Journal of Biological Chemistry*. 2015 Mar;290(10):6376–86.
45. Martínez Pérez LA, Becerra-Ruiz JS, García-Aviña JE, González-Sánchez GD, Martínez-Esquivias F, Vázquez-Jiménez SI, et al. Relation of serum IL-32 levels and gene polymorphism rs45499297 with obesity in Mexican patients: a laboratory and in silico

analysis. *Nutr Hosp* [Internet]. 2022 [cited 2024 Oct 1]; Available from: <https://www.nutricionhospitalaria.org/articles/03804/show>

46. Fadaei R, Bagheri N, Heidarian E, Nouri A, Hesari Z, Moradi N, et al. Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF- α and IL-6. *Cytokine*. 2020 Jan;125:154832.
47. Dhamoon AS, Jalife J. The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis. *Heart Rhythm*. 2005 Mar;2(3):316–24.
48. Chen K, Hu YY, Wang LL, Xia Y, Jiang Q, Sun L, et al. Whole-Genome Sequencing Identified KCNJ12 and SLC25A5 Mutations in Port-Wine Stains. *Front Med*. 2022 Jul 20;9:905902.
49. Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, et al. Physiological Role of Akt in Insulin-Stimulated Translocation of GLUT4 in Transfected Rat Adipose Cells. *Molecular Endocrinology*. 1997 Dec;11(13):1881–90.
50. Prashanth G, Vastrad B, Tengli A, Vastrad C, Kotturshetti I. Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules. *BMC Endocr Disord*. 2021 Dec;21(1):80.
51. Yang Z, Cheng J, Shang P, Sun JP, Yu X. Emerging roles of olfactory receptors in glucose metabolism. *Trends in Cell Biology*. 2023 Jun;33(6):463–76.
52. Cheng J, Yang Z, Ge XY, Gao MX, Meng R, Xu X, et al. Autonomous sensing of the insulin peptide by an olfactory G protein-coupled receptor modulates glucose metabolism. *Cell Metabolism*. 2022 Feb;34(2):240-255.e10.
53. Wang K, Li WD, Glessner JT, Grant SFA, Hakonarson H, Price RA. Large Copy-Number Variations Are Enriched in Cases With Moderate to Extreme Obesity. *Diabetes*. 2010 Oct 1;59(10):2690–4.
54. Ding L, Han L, Dube J, Billadeau DD. WASH Regulates Glucose Homeostasis by Facilitating Glut2 Receptor Recycling in Pancreatic β -Cells. *Diabetes*. 2019 Feb 1;68(2):377–86.
55. Galli M, Hameed A, Żbikowski A, Zabielski P. Aquaporins in insulin resistance and diabetes: More than channels! *Redox Biology*. 2021 Aug;44:102027.
56. Méndez-Giménez L, Ezquerro S, Da Silva IV, Soveral G, Frühbeck G, Rodríguez A. Pancreatic Aquaporin-7: A Novel Target for Anti-diabetic Drugs? *Front Chem*. 2018 Apr 5;6:99.
57. Bekri S, Kispal G, Lange H, Fitzsimons E, Tolmie J, Lill R, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. *Blood*. 2000 Nov 1;96(9):3256–64.

58. Schou J, Tybjærg-Hansen A, Møller HJ, Nordestgaard BG, Frikke-Schmidt R. ABC Transporter Genes and Risk of Type 2 Diabetes. *Diabetes Care*. 2012 Dec 1;35(12):2600–6.
59. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasani Z, et al. β -cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. *Nat Med*. 2007 Mar;13(3):340–7.
60. Frikke-Schmidt R. Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease. *JAMA*. 2008 Jun 4;299(21):2524.
61. Bowman P, Flanagan SE, Edghill EL, Damhuis A, Shepherd MH, Paisey R, et al. Heterozygous ABCC8 mutations are a cause of MODY. *Diabetologia*. 2012 Jan;55(1):123–7.
62. Ovsyannikova AK, Rymar OD, Shakhtshneider EV, Klimontov VV, Koroleva EA, Myakina NE, et al. ABCC8-Related Maturity-Onset Diabetes of the Young (MODY12): Clinical Features and Treatment Perspective. *Diabetes Ther*. 2016 Sep;7(3):591–600.
63. Pujar M, Vastrad B, Kavatagimath S, Vastrad C, Kotturshetti S. Identification of candidate biomarkers and pathways associated with type 1 diabetes mellitus using bioinformatics analysis. *Sci Rep*. 2022 Jun 1;12(1):9157.
64. Jinfeng M, Kimura W, Hirai I, Sakurai F, Moriya T, Mizutani M. Expression of MUC5AC and MUC6 in Invasive Ductal Carcinoma of the Pancreas and Relationship With Prognosis. *IJGC*. 2004;34(1):09–18.
65. Mousa M, Albarguthi S, Albreiki M, Farooq Z, Sajid S, El Hajj Chehadeh S, et al. Whole-Exome Sequencing in Family Trios Reveals De Novo Mutations Associated with Type 1 Diabetes Mellitus. *Biology*. 2023 Mar 7;12(3):413.